Early salvage radiation therapy post-prostatectomy: Key considerations

Alessandro Morlacco, Robert Jeffrey Karnes

Research output: Contribution to journalReview article

Abstract

Post-prostatectomy radiotherapy (RT) is commonly employed to maximize oncologic outcomes in patients with pathologic adverse features (adjuvant RT]) or to treat men with prostate-specific antigen or local recurrence after initial observation (salvage RT [SRT]). Randomized controlled trials have been unable to compare adjuvant RT versus SRT; however, there is growing retrospective evidence that observation and early SRT (eSRT) may be a suitable. The issue of patient selection is crucial; several clinical tools and some newer biomarker-based tools might help in this process. Moreover, the optimal prostate-specific antigen threshold for eSRT, the RT dose, the irradiation field and the use of hormonal therapy are still open questions. In this article, we review the current literature on eSRT and provide some insights on what's happening for the future.

Original languageEnglish (US)
Pages (from-to)2579-2587
Number of pages9
JournalFuture Oncology
Volume12
Issue number22
DOIs
StatePublished - Nov 1 2016

Fingerprint

Salvage Therapy
Prostatectomy
Secondary Prevention
Adjuvant Radiotherapy
Radiotherapy
Prostate-Specific Antigen
Observation
Patient Selection
Randomized Controlled Trials
Biomarkers
Recurrence
Therapeutics

Keywords

  • adjuvant
  • biomarkers
  • early salvage
  • predictive models
  • prostate cancer
  • prostatectomy
  • radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Early salvage radiation therapy post-prostatectomy : Key considerations. / Morlacco, Alessandro; Karnes, Robert Jeffrey.

In: Future Oncology, Vol. 12, No. 22, 01.11.2016, p. 2579-2587.

Research output: Contribution to journalReview article

@article{3e51c243e8f3418581d9fa093c53f9d0,
title = "Early salvage radiation therapy post-prostatectomy: Key considerations",
abstract = "Post-prostatectomy radiotherapy (RT) is commonly employed to maximize oncologic outcomes in patients with pathologic adverse features (adjuvant RT]) or to treat men with prostate-specific antigen or local recurrence after initial observation (salvage RT [SRT]). Randomized controlled trials have been unable to compare adjuvant RT versus SRT; however, there is growing retrospective evidence that observation and early SRT (eSRT) may be a suitable. The issue of patient selection is crucial; several clinical tools and some newer biomarker-based tools might help in this process. Moreover, the optimal prostate-specific antigen threshold for eSRT, the RT dose, the irradiation field and the use of hormonal therapy are still open questions. In this article, we review the current literature on eSRT and provide some insights on what's happening for the future.",
keywords = "adjuvant, biomarkers, early salvage, predictive models, prostate cancer, prostatectomy, radiation",
author = "Alessandro Morlacco and Karnes, {Robert Jeffrey}",
year = "2016",
month = "11",
day = "1",
doi = "10.2217/fon-2016-0208",
language = "English (US)",
volume = "12",
pages = "2579--2587",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "22",

}

TY - JOUR

T1 - Early salvage radiation therapy post-prostatectomy

T2 - Key considerations

AU - Morlacco, Alessandro

AU - Karnes, Robert Jeffrey

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Post-prostatectomy radiotherapy (RT) is commonly employed to maximize oncologic outcomes in patients with pathologic adverse features (adjuvant RT]) or to treat men with prostate-specific antigen or local recurrence after initial observation (salvage RT [SRT]). Randomized controlled trials have been unable to compare adjuvant RT versus SRT; however, there is growing retrospective evidence that observation and early SRT (eSRT) may be a suitable. The issue of patient selection is crucial; several clinical tools and some newer biomarker-based tools might help in this process. Moreover, the optimal prostate-specific antigen threshold for eSRT, the RT dose, the irradiation field and the use of hormonal therapy are still open questions. In this article, we review the current literature on eSRT and provide some insights on what's happening for the future.

AB - Post-prostatectomy radiotherapy (RT) is commonly employed to maximize oncologic outcomes in patients with pathologic adverse features (adjuvant RT]) or to treat men with prostate-specific antigen or local recurrence after initial observation (salvage RT [SRT]). Randomized controlled trials have been unable to compare adjuvant RT versus SRT; however, there is growing retrospective evidence that observation and early SRT (eSRT) may be a suitable. The issue of patient selection is crucial; several clinical tools and some newer biomarker-based tools might help in this process. Moreover, the optimal prostate-specific antigen threshold for eSRT, the RT dose, the irradiation field and the use of hormonal therapy are still open questions. In this article, we review the current literature on eSRT and provide some insights on what's happening for the future.

KW - adjuvant

KW - biomarkers

KW - early salvage

KW - predictive models

KW - prostate cancer

KW - prostatectomy

KW - radiation

UR - http://www.scopus.com/inward/record.url?scp=84992169506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992169506&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0208

DO - 10.2217/fon-2016-0208

M3 - Review article

C2 - 27387852

AN - SCOPUS:84992169506

VL - 12

SP - 2579

EP - 2587

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 22

ER -